Citius Oncology, Inc.

192 articles about Citius Oncology, Inc.

• Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update

  2/10/2023

  Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products reported business and financial results for the fiscal first quarter ended December 31, 2022.

• Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023

  1/11/2023

  Citius Pharmaceuticals, Inc. today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023.

• Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update

  12/22/2022

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2022.

• Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

  12/1/2022

  Citius Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Biologics License Application (BLA) for denileukin diftitox ("I/ONTAK" or "E7777"), an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).

• Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program

  11/21/2022

  Citius Pharmaceuticals, Inc. today announced that the Company has been selected to participate in New Jersey's Technology Business Tax Certificate Transfer (NOL) Program, more commonly known as the Net Operating Loss (NOL) Program, and will receive $3.6 million in non-dilutive capital through the New Jersey Economic Development Authority (NJEDA). Citius expects to receive the funds by late 2022 or early 2023.

• Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting

  11/9/2022

  Citius Pharmaceuticals, Inc. have been accepted for presentations at the prestigious 64th American Society of Hematology (ASH) Annual Meeting, to be held in New Orleans, December 10-13, 2022.

• Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022

  10/6/2022

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will be presenting at the Dawson James Securities Small Cap Growth Conference on October 12, 2022.

• 

  FDA Review: Amylyx, Sarepta, Sanofi-Regeneron and More

  9/30/2022

  The FDA had a busy week, approving drugs, greenlighting clinical trials and other regulatory activities for Immuneering, Amylyx, Sarepta, Sanofi, and Regeneron and more. 

• Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

  9/28/2022

  Citius Pharmaceuticals, Inc. today announced that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denileukin diftitox (I/ONTAK), an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).

• Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), today announced that Citius will participate in the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022.

• Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update

  8/11/2022

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today reported business and financial results for the third fiscal quarter of 2022 ended June 30, 2022.

• Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma

  7/12/2022

  Citius Pharmaceuticals, Inc.  today announced that the Company held a Type B pre-BLA meeting with the U.S. Food and Drug Administration (FDA) to discuss I/ONTAK (denileukin diftitox), an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).

• Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company

  5/25/2022

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it intends to split the Company's assets into two separate publicly-traded entities.

• Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022

  5/18/2022

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022.

• Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update

  5/12/2022

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today reported business and financial results for the second fiscal quarter of 2022 ended March 31, 2022.

• Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally

  5/6/2022

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has selected Biorasi, LLC ("Biorasi"), a global clinical research organization (CRO), to help expand the Company's Phase 3 Mino-Lok trial to additional sites outside the United States.

• Citius Pharmaceuticals, Inc. Provides Business Update, Highlights Upcoming Milestones

  5/3/2022

   Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today provided a business update for the first quarter ended March 31, 2022 and reported on recent corporate developments and upcoming milestones.

• Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

  4/26/2022

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the first patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido for the treatment of hemorrhoids.

• Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022

  4/14/2022

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), today announced that it will present at NobleCon18, Noble Capital Markets' 18th Annual Investor Conference.

• Citius Pharmaceuticals Announces Key Management Realignment to Support Commercialization of Two Late-Stage Product Candidates

  4/13/2022

  Citius Pharmaceuticals, Inc announced that the Board of Directors has approved key management changes to strengthen the Company's commercial capabilities as its two late Phase 3 programs for I/ONTAK and Mino-Lok® near completion.